| Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (NCT00534820) | King Faisal Specialist Hospital & Research Center | 2004-06-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL (NCT00186589) | Stanford University | 2004-05-01 |
| Family Study of Lymphoproliferative Disorders (NCT00626496) | Mayo Clinic | 2004-04-01 |
| Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (NCT00240565) | GlaxoSmithKline | 2004-04-01 |
| Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients (NCT00322387) | Genzyme, a Sanofi Company | 2004-04-01 |
| An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma (NCT00097565) | Genentech, Inc. | 2004-03-01 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients (NCT00322491) | Genzyme, a Sanofi Company | 2004-03-01 |
| Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma (NCT00117156) | Dana-Farber Cancer Institute | 2003-12-01 |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab (NCT00240578) | GlaxoSmithKline | 2003-11-01 |
| Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab (NCT00240591) | GlaxoSmithKline | 2003-10-01 |
| Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma (NCT00186355) | Stanford University | 2003-10-01 |
| ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia (NCT00114348) | Charite University, Berlin, Germany | 2003-08-01 |
| Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma (NCT00168727) | Biogen | 2003-06-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma (NCT00061672) | Abbott | 2003-04-01 |
| Randomized Double Cord Blood Transplant Study (NCT00067002) | M.D. Anderson Cancer Center | 2003-04-01 |
| Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma (NCT00232440) | University Health Network, Toronto | 2003-01-01 |
| Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's Lymphoma (NCT00082303) | National Center for Complementary and Integrative Health (NCCIH) | 2002-07-01 |
| Meaning-Centered Psychotherapy in Advanced Cancer (NCT00067288) | National Center for Complementary and Integrative Health (NCCIH) | 2002-05-01 |
| Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NCT00044551) | Bayer | 2002-02-01 |
| Genome Expression in Lymphoma, Leukemia and Multiple Myeloma (NCT00339963) | National Cancer Institute (NCI) | 2001-11-09 |
| Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation (NCT00154440) | Technische Universität Dresden | 2001-11-01 |
| Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy (NCT00185393) | Bayer | 2001-08-01 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |
| Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment (NCT00398372) | Stanford University | 2000-11-01 |
| A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy (NCT00261677) | Ortho Biotech Products, L.P. | 2000-08-01 |
| Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP (NCT01868035) | GlaxoSmithKline | 2000-05-01 |
| High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma (NCT00186394) | Stanford University | 2000-04-01 |
| Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma. (NCT01663714) | GlaxoSmithKline | 2000-02-01 |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement (NCT00992758) | GlaxoSmithKline | 1999-05-28 |
| Ultrasound Biomicroscopy - Apoptosis (NCT00188370) | University Health Network, Toronto | 1999-04-01 |
| Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease (NCT00398177) | Stanford University | 1999-01-01 |
| Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma (NCT00268203) | GlaxoSmithKline | 1998-09-01 |
| A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) (NCT01573000) | GlaxoSmithKline | 1998-09-01 |
| Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab (NCT00996593) | GlaxoSmithKline | 1998-07-01 |
| Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody (NCT00938041) | GlaxoSmithKline | 1998-04-01 |
| Large Cell Lymphoma Pilot Study III (NCT00187070) | St. Jude Children's Research Hospital | 1997-12-01 |
| Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia (NCT00001575) | National Cancer Institute (NCI) | 1997-04-01 |
| A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines (NCT00001571) | National Cancer Institute (NCI) | 1997-02-01 |
| Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma (NCT00989664) | GlaxoSmithKline | 1996-11-01 |
| Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma (NCT00996996) | GlaxoSmithKline | 1996-06-01 |
| Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (NCT01224821) | GlaxoSmithKline | 1995-12-01 |
| Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers (NCT00579163) | Memorial Sloan Kettering Cancer Center | 1994-12-01 |
| Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors (NCT00001301) | National Cancer Institute (NCI) | 1992-08-01 |
| Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma (NCT01536561) | GlaxoSmithKline | 1990-04-24 |
| Allo BMT in Advanced Leukemia or High Grade Lymphoma (NCT00186290) | Stanford University | 1989-12-01 |
| Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. (NCT00045864) | Chiron Corporation | |
| The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer (NCT00000723) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma (NCT00000689) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma (NCT00006434) | National Center for Research Resources (NCRR) | |
| Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma (NCT00002221) | Ribozyome | |
| Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas (NCT00002003) | Lederle Laboratories | |
| A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant (NCT00002284) | Glaxo Wellcome | |
| Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members (NCT00000703) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma (NCT00002348) | Genzyme, a Sanofi Company | |
| Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments (NCT00045877) | Chiron Corporation | |
| A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 (NCT01196208) | Seagen Inc. | |